Scope
This is NICE guideline NG106 on diagnosing and managing chronic heart failure in adults. It includes recommendations marked 2025 alongside retained earlier recommendations. It covers: - specialist and primary care team roles - natriuretic peptide–led diagnosis and echocardiography - medicine combinations by ejection fraction category The source defines reduced ejection fraction as 40% or less, mildly reduced as 41% to 49%, and preserved as 50% or more with structural criteria. It also covers dosing in chronic kidney disease, safety monitoring during titration, intravenous iron, clinical review and lifestyle advice. Further topics are devices and revascularisation, cardiac rehabilitation and palliative care. Several recommendations point to separate NICE technology appraisals or guidelines for full details.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Diagnosis and initial assessment
- Measure NT-proBNP when heart failure is suspected. Very high levels carry a poor prognosis, so above 2,000 nanogram per litre (236 picomole per litre) refer urgently for specialist assessment and transthoracic echocardiography within 2 weeks. For levels between 400 and 2,000 nanogram per litre (47 to 236 pmol per litre), refer within 6 weeks. Below 400 nanogram per litre in an untreated person, heart failure is less likely. In that case, review alternative causes and discuss with a heart failure subspecialist if concern persists. Levels do not distinguish ejection fraction categories. [1]
- Natriuretic peptide levels may be lowered by obesity, African or African–Caribbean ethnicity, or treatment with a diuretic, an ACE inhibitor, ARNI or ARB, a beta-blocker or an MRA. Raised levels can have non-cardiac causes, such as pulmonary, renal or liver disease, sepsis, COPD, diabetes or cirrhosis. [1]
- Use transthoracic echocardiography to exclude important valve disease, assess left ventricular function and detect intracardiac shunts. If image quality is poor, consider alternatives such as cardiac MRI, radionuclide angiography or transoesophageal echocardiography. Manage a historical diagnosis under this guideline only if cardiac imaging confirms it. [1]
- Perform an ECG. Consider other tests to look for aggravating factors or alternative diagnoses. These include renal, thyroid, liver and lipid profiles, HbA1c, full blood count, and peak flow or spirometry. [1]
Heart failure with reduced ejection fraction
- Offer an ACE inhibitor, a beta-blocker, an MRA and an SGLT2 inhibitor in combination. If symptoms persist at the maximum tolerated dose of all 4 medicines, consider switching the ACE inhibitor to an ARNI. [1]
- For ACE-inhibitor intolerance (other than angioedema), offer an ARNI with a beta-blocker, MRA and SGLT2 inhibitor. After ACE-inhibitor angioedema or with ARNI intolerance, offer a beta-blocker, MRA and SGLT2 inhibitor, and consider an ARB. [1]
- Assess iron status and check for anaemia using all three blood tests: transferrin saturation (TSAT), serum ferritin and haemoglobin. [1]
- Consider intravenous iron sucrose, ferric carboxymaltose or ferric derisomaltose when haemoglobin is less than 150 g per litre with iron deficiency. Iron deficiency is defined as TSAT less than 20% or ferritin less than 100 nanogram per ml. Do not assume iron deficiency anaemia is due to heart failure; think about investigating other causes. [1]
- If ACE inhibitors, ARNIs and ARBs are not tolerated, seek specialist advice and consider hydralazine plus nitrate. For worsening or severe disease despite optimised combinations, offer digoxin after seeking specialist advice. [1]
- Avoid verapamil, diltiazem and short-acting dihydropyridines in heart failure with reduced ejection fraction. [1]
Mildly reduced or preserved ejection fraction, and CKD
- For mildly reduced ejection fraction, consider an ACE inhibitor, beta-blocker, MRA and SGLT2 inhibitor. If ACE inhibitors are not tolerated, consider an ARB in place of the ACE inhibitor within the same combination. [1]
- For preserved ejection fraction, consider an MRA and an SGLT2 inhibitor. Finerenone is recommended as an option for both preserved and mildly reduced ejection fraction, with full details in NICE's technology appraisal guidance TA1182. [1]
- If eGFR is 45 ml per minute per 1.73 m2 or less, consider lower starting doses and smaller increments for the combinations in recommendations 1.4.1, 1.4.3, 1.4.4, and 1.5.1 to 1.5.7. If eGFR is less than 30 ml per minute per 1.73 m2, the specialist MDT should consider liaising with a renal physician. [1]
Starting and monitoring medicines
- Base decisions on the person's history, assessment, frailty, prognosis and preferences. This covers medicine choice and combinations, order and timing, initial doses and increments, and dose optimisation. Primary care prescribers should consider seeking specialist advice before starting an ARNI. [1]
- For ACE inhibitors, ARNIs, ARBs and MRAs: - Check renal function and electrolytes before prescribing. - Recheck 1 to 2 weeks after starting and after each increment. - Recheck every 3 to 6 months once the maximum tolerated dose is established, and any time renal function may be compromised. - Follow local guidelines if creatinine rises by more than 50% or potassium exceeds 5.5 mmol per litre. - Measure blood pressure (or have the person self-measure) before and after each increment. [1]
- Obtain a 12-lead ECG before prescribing a beta-blocker. Do not offer one in second- or third-degree heart block without a pacemaker, or in bradycardia (heart rate less than 50 beats per minute). Do not withhold beta-blockers solely because of age, COPD, diabetes or peripheral vascular disease. [1]
- Do not routinely monitor digoxin levels. A level measured within 8 to 12 hours of the last dose may help confirm suspected toxicity or non-adherence. [1]
Care organisation and clinical review
- The primary care team should maintain communication links across care settings and recall people at least every 6 months, including while specialist care continues. It takes over routine management once heart failure is stabilised and optimised. [1]
- Monitor all people with heart failure. As a minimum, reviews should cover: - function, fluid status, rhythm, cognition and nutrition - medicines, including needed changes and side effects - renal function - iron status and haemoglobin Review within days to every 2 weeks after clinical or medicine changes, and at least every 6 months when stable. [1]
Other treatments, devices, rehabilitation and palliative care
- Use diuretics for congestion at the lowest dose required. Do not routinely restrict sodium or fluid. Instead, ask about intake and, if needed, advise fluid restriction for dilutional hyponatraemia, or reduced intake for those with high salt or fluid consumption. Keep the need for restriction under review. Advise avoiding potassium-containing salt substitutes. [1]
- Offer annual influenza vaccination and one-off pneumococcal vaccination. [1]
- Do not routinely offer coronary revascularisation for reduced ejection fraction with coronary artery disease. Review the benefits and potential harms of an implanted defibrillator remaining active at each 6-monthly review and when care goals change. Also review this during advance care planning if the person is thought to be nearing the end of life. [1]
- Offer a personalised, exercise-based cardiac rehabilitation programme. It should follow a suitability assessment and include psychological and educational components. [1]
- Do not offer long-term home oxygen for advanced heart failure, although it may be offered for comorbidities such as some cases of COPD. Do not use prognostic risk tools to decide palliative referral. If symptoms worsen despite optimal specialist treatment, discuss palliative needs with the MDT. [1]
Limitations and use
- Acute heart failure is excluded; the source refers to NICE's separate acute heart failure guideline.
- Full eligibility details for ivabradine, finerenone, SGLT2 inhibitors, ICDs/CRT and potassium binders are in referenced NICE technology appraisals and are not reproduced.
- Digoxin and anticoagulation in atrial fibrillation, depression, smoking, alcohol, hypertension-related blood pressure measurement and heart valve disease are deferred to other NICE guidance.
- The reviewed source excluded the research recommendations, update-history and committee-information chapters. Rationale and practice-impact text appeared only as inline committee sections within the recommendations; this summary is based on the recommendations themselves. Visual algorithms were represented only by their alternative text.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Chronic heart failure in adults: diagnosis and management
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 12 September 2018
- Publisher’s latest update
- 3 September 2025
- Resource type
- Clinical guideline · House clinical summary
Earlier House summaries: chronic heart failure in adults nice
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.